

# JAGSONPAL PHARMACEUTICALS LIMITED

CIN: L74899DL1978PLC009181

Registered Office: T-210 J, Shahpur Jat, New Delhi – 110049

Phone: 011-46181100 & 46109900, FAX: 011-26498341

Website: [www.jagsonpal.com](http://www.jagsonpal.com) , E-mail: [nandita.singh@jagsonpal.com](mailto:nandita.singh@jagsonpal.com)

Date: May 27 <sup>th</sup> , 2020	
The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager Listing Agreement The BSE Limited Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
<b>CM Quote : JAGSNPHARM</b>	<b>SCRIP Code : 507789</b>
<b>Subject: Submission of Certificate under Sub- Regulation 9 &amp; 10 Regulation 40 of the SEBI (Listing Obligations &amp; Disclosure Requirement) Regulations, 2015 for the half year ended 31<sup>st</sup> March, 2020.</b>	

Dear Sir & Madam,

Pursuant to the provisions of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations' "), please find enclosed herewith the Certificate dated May 26, 2020 for the half year ended March 31<sup>st</sup>, 2020. This certificate has been issued by Mr. Mukesh Arora proprietor of M/s Mukesh Arora & Co.

You are requested to take the above information on record.

**For Jagsonpal Pharmaceuticals Limited**

SD/-

Nandita Singh

Company Secretary & Compliance Officer

M. No. A48520



**CERTIFICATE UNDER REGULATION 40 (9) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**FOR THE HALF YEAR ENDED ON 31<sup>ST</sup> MARCH, 2020**

I have examined all share transfer deeds, memorandum of transfers, sub-division, consolidation, renewal, exchange or endorsement of calls/ allotment monies, registers, files and other documents relating to **JAGSONPAL PHARMACEUTICALS LIMITED** maintained by **MCS SHARE TRANSFER AGENT LIMITED** pertaining to transfer of equity shares of the company for the period from 1<sup>st</sup> October, 2019 to 31<sup>st</sup> March, 2020 for the purpose of issuing a Certificate as per Regulation 40 (9) of (Listing Obligations and Disclosure Requirements) Regulations, 2015 entered into by, **JAGSONPAL PHARMACEUTICALS LIMITED** with BSE and NSE and based on the information provided by the Company, I hereby certify that the Company has delivered during half year ended on 31<sup>st</sup> March, 2020:

Share Certificates relating to the Share transferred to IEPF received during the period from 1<sup>st</sup> October, 2019 to 31<sup>st</sup> March, 2020 as entered in the memorandum of transfers from respective date of lodgment of each deed.

There was no case of transfer, transmission, sub-division, split, duplicate, consolidation, renewal, exchange or endorsement of calls/allotment monies from respective date of lodgment of each deed with this period.

**Place: New Delhi**

**Date: 26.05.2020**

**FOR MUKESH ARORA & CO.  
COMPANY SECRETARY**

**(MUKESH ARORA – PROP.)**

**F.C.S.4819**

**C.P. 4405**

**UDIN NO: F004819B000283724**